BTK and B-cell chronic lymphocytic leukemia: Results on 94 patients with CLL/SLL (median 4 prior therapies, including a BTK inhibitor in 84%, a PI3K inhibitor in 21%, and venetoclax in 31%) enrolled in the phase 1/2 BRUIN trial of LOXO-305 were recently presented49.